select a format

Single User License
USD 2000 INR 129980
Site License
USD 4000 INR 259960
Corporate User License
USD 6000 INR 389940

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Constipation-Pipeline Review, H2 2015

Constipation-Pipeline Review, H2 2015


  • Products Id :- GMDHC6864IDB
  • |
  • Pages: 106
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Constipation-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Constipation-Pipeline Review, H2 2015', provides an overview of the Constipation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Constipation

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Constipation and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Constipation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Constipation pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Constipation

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Constipation Overview 9

Therapeutics Development 10

Pipeline Products for Constipation-Overview 10

Pipeline Products for Constipation-Comparative Analysis 11

Constipation-Therapeutics under Development by Companies 12

Constipation-Therapeutics under Investigation by Universities/Institutes 14

Constipation-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Constipation-Products under Development by Companies 18

Constipation-Products under Investigation by Universities/Institutes 20

Constipation-Companies Involved in Therapeutics Development 21

AlbireoPharma 21

Ardelyx, Inc. 22

Astellas Pharma Inc. 23

Braintree Laboratories, Inc. 24

Daiichi Sankyo Company, Limited 25

Dong-A Socio Group 26

Ironwood Pharmaceuticals, Inc. 27

Kissei Pharmaceutical Co., Ltd. 28

RaQualia Pharma Inc. 29

Rhythm Pharmaceuticals 30

Sanwa Kagaku Kenkyusho Co., Ltd. 31

Shire Plc 32

SK Biopharmaceuticals Co., Ltd. 33

Sucampo Pharmaceuticals, Inc. 34

Sumitomo Dainippon Pharma Co., Ltd. 35

Synergy Pharmaceuticals, Inc. 36

Constipation-Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Target 38

Assessment by Mechanism of Action 40

Assessment by Route of Administration 42

Assessment by Molecule Type 44

Drug Profiles 46

ASP-7663-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

BLI-400-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

DA-6886-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

DS-3801-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

DSP-6952-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

elobixibat-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

KWA-0711-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

linaclotide-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

lubiprostone-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

plecanatide-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

prucalopride succinate-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

relamorelin-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

relenopride hydrochloride-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

RQ-00000010-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

SK-1202-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Small Molecule to Activate 5-HT1 Receptor for Constipation and Dyspepsia-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

tenapanor hydrochloride-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Transilon-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Constipation-Recent Pipeline Updates 73

Constipation-Dormant Projects 96

Constipation-Product Development Milestones 97

Featured News & Press Releases 97

Jul 08, 2015: AstraZeneca and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Designed to Support Linaclotide Approval in China 97

Jun 17, 2015: Synergy Pharmaceuticals Announces Positive Results in the First Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation 98

Jun 15, 2015: China Food and Drug Administration Accepts IND for Pivotal Study of AMITIZA 100

Jun 03, 2015: Shire Receives European Approval to Use Resolor (prucalopride) in Men for the Symptomatic Treatment of Chronic Constipation 101

May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week 101

Jan 30, 2015: AMITIZA (lubiprostone) Mutual Recognition Procedure Closes With Recommendation for Approval in European Countries 102

Jan 29, 2015: Synergy Pharmaceuticals Completes Patient Enrollment for the Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation 102

Jan 08, 2015: Synergy Pharmaceuticals Completes Patient Enrollment for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation 102

Nov 20, 2014: Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan 103

Nov 12, 2014: Sucampo Files Patent Infringement Lawsuit Against Dr. Reddy's 103

Appendix 105

Methodology 105

Coverage 105

Secondary Research 105

Primary Research 105

Expert Panel Validation 105

Contact Us 105

Disclaimer 106

List of Tables

Number of Products under Development for Constipation, H2 2015 10

Number of Products under Development for Constipation-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 14

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Products under Development by Companies, H2 2015 18

Products under Development by Companies, H2 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H2 2015 20

Constipation-Pipeline by AlbireoPharma, H2 2015 21

Constipation-Pipeline by Ardelyx, Inc., H2 2015 22

Constipation-Pipeline by Astellas Pharma Inc., H2 2015 23

Constipation-Pipeline by Braintree Laboratories, Inc., H2 2015 24

Constipation-Pipeline by Daiichi Sankyo Company, Limited, H2 2015 25

Constipation-Pipeline by Dong-A Socio Group, H2 2015 26

Constipation-Pipeline by Ironwood Pharmaceuticals, Inc., H2 2015 27

Constipation-Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015 28

Constipation-Pipeline by RaQualia Pharma Inc., H2 2015 29

Constipation-Pipeline by Rhythm Pharmaceuticals, H2 2015 30

Constipation-Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2015 31

Constipation-Pipeline by Shire Plc, H2 2015 32

Constipation-Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015 33

Constipation-Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015 34

Constipation-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 35

Constipation-Pipeline by Synergy Pharmaceuticals, Inc., H2 2015 36

Assessment by Monotherapy Products, H2 2015 37

Number of Products by Stage and Target, H2 2015 39

Number of Products by Stage and Mechanism of Action, H2 2015 41

Number of Products by Stage and Route of Administration, H2 2015 43

Number of Products by Stage and Molecule Type, H2 2015 45

Constipation Therapeutics-Recent Pipeline Updates, H2 2015 73

Constipation-Dormant Projects, H2 2015 96

List of Figures

Number of Products under Development for Constipation, H2 2015 10

Number of Products under Development for Constipation-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Products, H2 2015 17

Assessment by Monotherapy Products, H2 2015 37

Number of Products by Top 10 Targets, H2 2015 38

Number of Products by Stage and Top 10 Targets, H2 2015 38

Number of Products by Top 10 Mechanism of Actions, H2 2015 40

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 40

Number of Products by Top 10 Routes of Administration, H2 2015 42

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 42

Number of Products by Top 10 Molecule Types, H2 2015 44

Number of Products by Stage and Top 10 Molecule Types, H2 2015 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AlbireoPharma

Ardelyx, Inc.

Astellas Pharma Inc.

Braintree Laboratories, Inc.

Daiichi Sankyo Company, Limited

Dong-A Socio Group

Ironwood Pharmaceuticals, Inc.

Kissei Pharmaceutical Co., Ltd.

RaQualia Pharma Inc.

Rhythm Pharmaceuticals

Sanwa Kagaku Kenkyusho Co., Ltd.

Shire Plc

SK Biopharmaceuticals Co., Ltd.

Sucampo Pharmaceuticals, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Synergy Pharmaceuticals, Inc.

Constipation Therapeutic Products under Development, Key Players in Constipation Therapeutics, Constipation Pipeline Overview, Constipation Pipeline, Constipation Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com